Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Benitec Biopharma (BNTC) Non Operating Income (2019 - 2025)

Benitec Biopharma (BNTC) has disclosed Non Operating Income for 7 consecutive years, with -$126000.0 as the latest value for Q2 2025.

  • Quarterly Non Operating Income fell 9.57% to -$126000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Jun 2025, up 504.88% year-over-year, with the annual reading at -$131000.0 for FY2025, 35.78% up from the prior year.
  • Non Operating Income hit -$126000.0 in Q2 2025 for Benitec Biopharma, down from $1.3 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $1.3 million in Q4 2024 to a low of -$513000.0 in Q3 2022.
  • Historically, Non Operating Income has averaged -$21588.2 across 5 years, with a median of -$80000.0 in 2023.
  • Biggest five-year swings in Non Operating Income: tumbled 1438.1% in 2021 and later soared 7931.25% in 2024.
  • Year by year, Non Operating Income stood at $14000.0 in 2021, then skyrocketed by 1321.43% to $199000.0 in 2022, then crashed by 108.04% to -$16000.0 in 2023, then skyrocketed by 7931.25% to $1.3 million in 2024, then plummeted by 110.06% to -$126000.0 in 2025.
  • Business Quant data shows Non Operating Income for BNTC at -$126000.0 in Q2 2025, $1.3 million in Q4 2024, and $35000.0 in Q3 2024.